Explore and download PhRMA's first-ever health equity chart pack. This chart pack spotlights the patient experience in the health care system, recognizing and visualizing the structural and social inequities that underserved communities face when seeking health care services and medicines.
Medicare is the government program that insures many of the nation’s retirees and Americans with disabilities. Coverage for prescription medicines filled at a pharmacy first became available in 2006 under the Medicare Part D program. Private health plans administer the program and compete for beneficiary enrollment. These plans also negotiate with manufacturers, without government interference, to secure to secure savings on medicines. This market-based approach has been successful since the program’s beginning, but some in Washington now are considering fundamental change.
Medicaid provides health insurance for 1 in 5 vulnerable Americans, including children, pregnant women, seniors, and those with serious diseases, providing them with access to needed medications with low to no cost sharing.
The 340B program was originally created in 1992 to help safety-net facilities, like clinics and hospitals, that serve a large number of vulnerable or uninsured patients. The program requires pharmaceutical manufacturers to provide steep discounts to these facilities as a condition of their medicines being covered by Medicaid. Today, however, the 340B program bears little resemblance to what Congress envisioned.
Medicare is the government program that insures many of the nation’s retirees and Americans with disabilities. This chapter contains information on prescription drug coverage under Part B, which generally covers medications administered by a physician, like injected or infused vaccines and medicines. The medicines covered by Part B represent significant medical advances, including breakthroughs in cancer, rheumatoid arthritis, and autoimmune conditions.
The US Department of Veterans Affairs (VA) offers some health care services and coverage to a special population – veterans with service-related disabilities and, in some cases, their families. The VA offers a narrower drug benefit and serves a smaller population than Medicare and Medicaid. Many veterans use other coverage for their medicines rather than rely exclusively on VA coverage.
The latest Cancer Medicines Value in Context chart pack dives deep into the research to illustrate how the biopharmaceutical industry leads the fight against the more than 200 diseases we call cancer.
Collectively, rare diseases aren't so rare. This chart pack explores how orphan medicines and venture capital investment meet the need and help 30 million Americans.
This chart pack provides facts and figures about the promise of personalized medicine in delivering the right treatment to the right patient at the right dose the first time through the use of molecular biomarker tests and targeted therapies.